New drug duo targets hard-to-treat HER2 cancers
Disease control
Not yet recruiting
This study is testing a new drug called BM230 combined with a PD-1 inhibitor (a type of immunotherapy) in people with advanced solid tumors that are related to HER2. The goal is to find the best dose and see if the combination is safe and can shrink tumors. The trial includes sev…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Biomissile Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC